

Imaging Response in the Primary Index Lesion and Clinical Outcomes Following Transarterial Locoregional Therapy for Hepatocellular Carcinoma

Ahsun Riaz, MD

Frank H. Miller, MD

Laura M. Kulik, MD

Paul Nikolaidis, MD

Vahid Yaghmai, MD

Robert J. Lewandowski, MD

Mary F. Mulcahy, MD

Robert K. Ryu, MD

Kent T. Sato, MD

Ramona Gupta, MD

Ed Wang, PhD

Talia Baker, MD

Michael Abecassis, MD

Al B. Benson III, MD

Albert A. Nemcek Jr, MD

Reed Omary, MD

Riad Salem, MD, MBA

THE INCIDENCE OF HEPATOCELLULAR carcinoma (HCC) is increasing worldwide.¹ Curative surgical therapies have demonstrated the best long-term survival rates; however, most patients do not meet selection criteria.² Sorafenib is the sole systemic agent that has shown a survival benefit for advanced HCC.³ Locoregional therapies (LRTs) deliver toxic thermal, chemical, and/or radioactive doses to tumors, with acceptable toxicity to normal tissue. Chemoembolization and radioembolization using yttrium 90 (⁹⁰Y) are transarterial LRTs that have a palliative role in HCC.⁴⁻⁷

Context Response Evaluation Criteria in Solid Tumors (RECIST) (unidimensional), World Health Organization (WHO) (bidimensional), and European Association for Study of the Liver (EASL) (necrosis) guidelines are commonly used to assess response following therapy for hepatocellular carcinoma (HCC). No universally accepted standard exists.

Objectives To evaluate intermethod agreement between these 3 imaging guidelines and to introduce the concept of the “primary index lesion” as a biomarker for response.

Design, Setting, and Participants Single-center comprehensive imaging analysis including 245 consecutive patients with HCC who were treated with chemoembolization or radioembolization between January 2000 and December 2008. Computed tomography and magnetic resonance imaging scans (N=1065) were reviewed to assess response in the “primary index lesion,” defined as the largest tumor targeted during first treatment.

Main Outcome Measures Intermethod agreement (κ statistics) between RECIST, WHO, and EASL guidelines response; correlation of WHO and EASL response in the primary index lesion with time to progression and survival.

Results κ Coefficients were 0.86 (95% confidence interval [CI], 0.80-0.92) between the WHO and RECIST guidelines, 0.24 (95% CI, 0.16-0.33) between RECIST and EASL, and 0.28 (95% CI, 0.19-0.36) between WHO and EASL. Disease progressed in 96 patients; 113 died. The hazard ratio for time to progression in responders compared with nonresponders was 0.36 (95% CI, 0.23-0.57) for WHO, 0.38 (95% CI, 0.24-0.58) for RECIST, and 0.38 (95% CI, 0.22-0.64) for EASL. Hazard ratios for survival in responders compared with nonresponders in univariate and multivariate analyses were 0.46 (95% CI, 0.32-0.67) and 0.55 (95% CI, 0.35-0.84) for WHO and 0.36 (95% CI, 0.22-0.57) and 0.54 (95% CI, 0.34-0.85) for EASL. Hazard ratios for survival in responders vs nonresponders in patients with solitary and multifocal HCC were 0.39 (95% CI, 0.19-0.77) and 0.51 (95% CI, 0.32-0.82) for WHO and 0.26 (95% CI, 0.10-0.67) and 0.47 (95% CI, 0.28-0.79) for EASL.

Conclusions Among a group of patients with HCC, agreement for classification of therapeutic response was high between the RECIST and WHO guidelines but low between each of these and EASL. Application of these methods to measure response in a primary index lesion resulted in statistically significant correlations with disease progression and survival.

JAMA. 2010;303(11):1062-1069

www.jama.com

Author Affiliations: Department of Radiology, Northwestern Memorial Hospital, Robert H. Lurie Comprehensive Cancer Center (Drs Riaz, Miller, Nikolaidis, Yaghmai, Lewandowski, Ryu, Sato, Gupta, Nemcek, Omary, and Salem); Departments of Medicine, Division of Hepatology (Dr Kulik) and Transplant Surgery (Drs Wang, Baker, Abecassis, and Salem); and Department of Medicine, Division

of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center (Drs Mulcahy, Benson, and Salem), Northwestern University, Chicago, Illinois.

Corresponding Author: Riad Salem, MD, MBA, Interventional Oncology, Department of Radiology, 676 N St Clair, Ste 800, Chicago, IL 60611 (r-salem@northwestern.edu)

Given the lack of standardization of functional imaging in HCC, anatomical methods are still considered the gold standard for response assessment. In 1979, the World Health Organization (WHO) (bidimensional perpendicular measurements) published guidance on the anatomical assessment of tumor response to therapy.⁸ In 2000, the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (unidimensional measurements) were published, updating the WHO document.⁹ While the original intent of the WHO and RECIST guidelines was to describe methods for assessing response following systemic chemotherapies in which all tumors are theoretically equally exposed to systemic agents, this approach does not directly translate to LRTs. These therapies are usually staged procedures and do not target all disease in a single treatment session; they often cause tumor necrosis without change in tumor size.^{10,11} In response to these limitations, the European Association for Study of the Liver (EASL) guidelines were published in 2001 and were based on percent change in amount of enhancing tumoral tissue posttreatment.^{9,10,12} Most recently, the revised RECIST guidelines (version 1.1) advocated assessing response using fewer lesions (≤ 2 per organ) than the original RECIST guidelines (≤ 5 per organ), suggesting that the optimal number of lesions that should be measured remains uncertain.^{13,14}

We performed 2 comprehensive analyses in 245 patients treated with transarterial LRT. Because the WHO and RECIST guidelines have been shown to be similar in their ability to capture response and investigators have demonstrated minimal agreement between RECIST and EASL,¹⁰ we sought to validate these concepts following transarterial LRTs.¹⁵ Our first analysis addressed the question: Is there agreement in response between the RECIST (unidimensional), WHO (bidimensional), and EASL (necrosis) guidelines?

Given that the single common factor for all patients undergoing transar-

terial therapy is that they have at least 1 dominant first-treated lesion, we hypothesized that this lesion may be prospectively identified as the "primary index lesion" for that patient and that response measurement using that lesion alone may be considered a predictor for time to progression (TTP) and survival. Investigators have shown that imaging response may predict survival benefit; the ability of response in the primary index lesion to capture a TTP benefit would further strengthen this concept.¹⁶ Therefore, our second analysis sought to assess whether RECIST, WHO, or EASL response was predictive of a therapeutic (TTP and survival) benefit when compared with patients not exhibiting response by using the primary index lesion alone, irrespective of multifocality; ie, Does an imaging response in the primary index lesion correlate with improved TTP and survival in solitary or multifocal disease? This would result in a simple, reproducible, and standardizable methodology for assessing response in HCC.

METHODS

Consecutive patients with HCC (without vascular invasion or extrahepatic metastases) who were treated with transarterial LRTs (chemoembolization and radioembolization) at our institution between January 2000 and December 2008 were included. This study was approved by the Northwestern University institutional review board and complied with the Health Insurance Portability and Accountability Act. All patients provided written informed consent for treatment.

Evaluation and Staging

Diagnosis of HCC was confirmed by biopsy or radiographic findings using accepted guidelines.¹⁷ Baseline characteristics were obtained; patients were staged using Child-Pugh, United Network for Organ Sharing (UNOS), and Barcelona Clinic Liver Cancer (BCLC) classification systems.^{18,19} Patients were classified as BCLC class C if they exhibited HCC-related symptoms (eg, capsular pain). The decision to treat

with chemoembolization or radioembolization was based on consensus of a multidisciplinary team at a weekly HCC conference of hepatologists, medical oncologists, transplant surgeons, and interventional radiologists.

Treatment

Chemoembolization is a transarterial therapy that delivers high doses of chemotherapeutic agents to a tumor via the hepatic artery. It was performed using the standard triple-drug mixture of mitomycin (30 mg), adriamycin (30 mg), and cisplatin (100 mg) mixed with lipiodol; this was followed by delivery of permanent embolic particles. Technical details of chemoembolization have been discussed elsewhere.²⁰

Radioembolization using ⁹⁰Y is a transarterial therapy in which high doses of radioactivity are delivered to the tumor via the hepatic artery. The device used was glass-based (TheraSphere; MDS Nordion, Ottawa, Ontario, Canada), with ⁹⁰Y as an integral constituent of the 20- to 30- μ m microspheres. Technical details of radioembolization have been discussed elsewhere.²¹

Imaging Analyses

Contrast-enhanced computed tomography or gadolinium-enhanced magnetic resonance imaging were used for response assessment. The primary index lesion was defined as the lesion targeted during the first treatment session. It was usually the largest and was considered to be the most appropriate target for first transarterial therapy. For this analysis, even if several tumors were targeted during the first or subsequent treatments with chemoembolization or radioembolization, only the primary index lesion was used to assess response and followed longitudinally, even if it was not the lesion most recently treated. Lesions other than the primary index lesion are therefore analogous to nontarget lesions as defined by RECIST and hence not used for response assessment.

Response rates were assessed using size (WHO, RECIST) and necrosis

(EASL) guidelines.^{9,10,12} For purposes of WHO and RECIST measurements, the entire lesion was measured, irrespective of the amount of necrosis seen. This was deemed most conservative.

All calculations for imaging analyses were performed from the date of first LRT. Imaging follow-up (and hence measurement of the primary index lesion) was performed at 1 month following each treatment; subsequent scans were performed at scheduled 2- to 3-month intervals as per standard of care. The WHO, RECIST, and EASL guidelines used for this analysis are outlined in eTable 1.^{8,9,12}

Statistical Analyses

Intermethod Agreement. Intermethod agreement was assessed using κ statistics; a κ coefficient of 0.75 to 0.80 represents excellent intermethod agreement.^{22,23} There are 2 rationales for correlating RECIST and WHO. First, lesions are never completely spherical and often change shape following treatment; capturing only the largest single dimension (ie, using RECIST guidelines) may underestimate response (and conversely progression) when compared with the cross-product of the largest dimension and its perpendicular dimension (ie, using WHO guidelines). Second, the identification of a sample size at which RECIST (unidimensional) and WHO (bidimensional) become equivalent is of clinical relevance, because it may identify a minimum number of patients at which the 2 guidelines become interchangeable. To search for a sample size at which there would be excellent intermethod agreement between RECIST and WHO guidelines, we calculated κ at increments of 25 random patients per treatment group, with final κ coefficients based on all 245 patients.

Time to Response. Times to response (defined as complete or partial response) were calculated from the date of first treatment session using the Kaplan-Meier method and were compared using the log-rank test.²⁴ For purposes of calculating time to response, an end point was defined as imaging

response in the primary index lesion using either WHO, RECIST, or EASL guidelines.

Time to Progression and Survival. Time to progression and survival were calculated from the date of first treatment session using the Kaplan-Meier method and compared using the log-rank test.²⁴ Importantly, for purposes of calculating TTP, an end point was defined as any of the following: progression by WHO guidelines (>25% increase in the cross-product of the index lesion), EASL guidelines (>25% increase in the amount of enhancing tissue in the index lesion), UNOS stage (progressing from a less advanced to more advanced stage, eg, T4a to T4b), or appearance of new lesions or extrahepatic metastases. Survival calculations were censored to transplantation or resection.²⁵

In the case of a solitary HCC, the solitary, measurable tumor is by definition the primary index lesion. Therefore, the concept of assessing response using the primary index lesion alone is confounded only in cases of multifocal disease. The ability to validate the index lesion concept is based on the fact that nearly half of our cohort (112/245 patients [46%]) had a solitary HCC. Therefore, we were able to perform substratification analyses by tumor distribution (solitary vs multifocal HCC) to assess if the hazard ratios (HRs) for survival using only the primary index lesion for response assessment remained significant; HRs indicating a significant survival benefit in responders vs nonresponders in solitary and multifocal disease would suggest the ability to capture therapeutic benefit using the primary index lesion, despite the presence of multifocal disease.

Univariate and multivariate analyses were conducted to identify factors associated with survival. Race/ethnicity (white, Asian, Hispanic, African American) was assessed by the physician and was studied for univariate analysis but not included as a variable in the multivariate analysis. Univariate analysis was performed using the Kaplan-Meier method with the log-rank test, and mul-

tivariate analyses were performed using the Cox proportional hazards model.²⁶ Only variables having $P < .05$ on univariate analysis were included in the multivariate model, and the HR estimates were based on simultaneous analysis of all predicated variables. Assumption of proportionality was tested using the log-minus-log plot and was met. We used Child-Pugh class, UNOS stage, and Eastern Cooperative Oncology Group (ECOG) performance status to determine the effect of liver function, tumor stage, and performance status on survival.

Power Analysis. Our power analysis indicated that using the Cox regression of the log HR with an anticipated event rate of 0.45, a sample of 245 patients will achieve 81% power at a 2-tailed .05 significance level to detect a minimum HR of 1.33 for any given covariate.²⁷ Thus, our study is powered to detect any HRs greater than 1.33 or less than 0.75 (1/1.33).

All analyses were conducted using SAS version 9.2 (SAS Inc, Cary, North Carolina). All P values were 2-sided, and $P < .05$ was considered statistically significant.

RESULTS

Patient Sample, Treatment, and Imaging

TABLE 1 summarizes the baseline patient demographics for the 245-patient cohort. Of these, 122 patients (49%) were treated with chemoembolization and 123 (51%) with radioembolization. One hundred thirty-nine patients (57%) were diagnosed by imaging; 106 (43%) required biopsy. The median (interquartile range) number of treatments was 2 (1-3) for chemoembolization and 1 (1-2) for radioembolization ($P = .09$). Otherwise, the groups were similar. The median follow-up time was 13.8 months (95% confidence interval [CI], 12.1-17.0).

All 245 patients underwent imaging, and none were lost to follow-up; 1065 scans were reviewed (mean, 4.3 scans/patient). These data served as the source data for all imaging analyses described in this study.

Response Rates

In the WHO (bidimensional) analysis, complete response was seen in 4 patients (1.6%), partial response in 100 (40.8%), stable disease in 108 (44.1%), and progressive disease in 33 (13.5%). The median time to WHO response was 7.7 months (95% CI, 6.1-9.5).

In the RECIST (unidimensional) analysis, complete response was seen in 4 patients (1.6%), partial response in 97 (39.6%), stable disease in 114 (46.5%), and progressive disease in 30 (12.3%). The median time to RECIST response was 7.7 months (95% CI, 6.2-10.3).

In the EASL (necrosis) analysis, complete response was seen in 79 patients (32.2%), partial response in 93 (38%), stable disease in 54 (22%), and progressive disease in 19 (7.8%). The median time to EASL response was 1.6 months (95% CI, 1.3-2.2).

Intermethod Agreement

TABLE 2 represents the intermethod agreement of the WHO and RECIST guidelines. The κ coefficient increased with the number of patients. The number of patients in whom a κ of 0.8 was reached was 50 (25 per group). The κ between WHO and RECIST for all 245 patients was 0.86 (95% CI, 0.80-0.92).

TABLE 3 presents the κ between EASL and WHO and RECIST. The κ for EASL and RECIST was 0.24 (95% CI, 0.16-0.33). The κ for EASL and WHO was 0.28 (95% CI, 0.19-0.36).

Response and Long-term Outcomes

Time to Progression. Disease progressed in 96 patients. The HRs for TTP in responders compared with nonresponders by WHO, RECIST, and EASL guidelines were 0.36 (95% CI, 0.23-0.57), 0.38 (95% CI, 0.24-0.58), and 0.38 (95% CI, 0.22-0.64), respectively.

Survival. One hundred thirteen patients died. The HRs for survival in responders compared with nonresponders by WHO, RECIST, and EASL guidelines were 0.46 (95% CI, 0.32-0.67), 0.46 (95% CI, 0.31-0.66), and 0.36 (95% CI, 0.22-0.57), respectively.

TTP and Survival. TABLE 4 presents TTP and survival comparisons between responders and nonresponders when WHO and EASL guidelines were applied, substratified by solitary and multifocal disease. Significant HRs between responders and nonresponders were seen for the response guidelines between solitary and

Table 1. Baseline Characteristics of Patients With Hepatocellular Carcinoma

Characteristic	No. (%)			P Value ^a
	Total (n = 245)	Chemoembolization (n = 122)	Radioembolization (n = 123)	
Age, y				
<65	134 (55)	78 (64)	56 (46)	.006
≥65	111 (45)	44 (36)	67 (54)	
Race/ethnicity				
White	170 (69)	79 (65)	91 (74)	.40
Asian	25 (10)	13 (11)	12 (10)	
Hispanic	24 (10)	15 (12)	9 (7)	
African American	26 (11)	15 (12)	11 (9)	
Sex				
Male	189 (77)	102 (84)	87 (71)	.14
Female	56 (23)	20 (16)	36 (29)	
Etiology				
Alcohol	41 (17)	21 (17)	20 (16)	.24
HCV	98 (40)	56 (46)	42 (35)	
HCV + alcohol	8 (3)	2 (2)	6 (4)	
HBV	25 (10)	12 (10)	13 (11)	
NASH	6 (2)	1 (1)	5 (4)	
Cryptogenic	53 (22)	25 (20)	28 (23)	
Unknown	14 (6)	5 (4)	9 (7)	
Pretreatment α -fetoprotein >200 ng/mL				
Yes	77 (31)	37 (30)	40 (33)	.82
No	168 (69)	85 (70)	83 (67)	
Cirrhosis				
Present	218 (88)	112 (92)	106 (86)	.22
Absent	27 (12)	10 (8)	17 (14)	
Tumor size, median (IQR), cm	4 (2.9-6.1)	3.6 (2.6-5.7)	4.5 (3.1-6.6)	.10
Tumor distribution				
Solitary	112 (46)	57 (47)	55 (45)	.85
Multifocal	133 (54)	65 (53)	68 (55)	
Child-Pugh class				
A	134 (55)	67 (55)	67 (54)	.99
B	107 (43)	53 (43)	54 (44)	
C	4 (2)	2 (2)	2 (2)	
BCLC stage				
A	90 (37)	47 (39)	43 (35)	.95
B	126 (51)	61 (50)	65 (53)	
C	25 (10)	12 (9)	13 (10)	
D	4 (2)	2 (2)	2 (2)	
UNOS stage				
T1	5 (2)	4 (3)	1 (1)	.44
T2	90 (37)	46 (38)	44 (36)	
T3	78 (32)	35 (29)	43 (35)	
T4a	72 (29)	37 (30)	35 (28)	

Abbreviations: BCLC, Barcelona Clinic Liver Cancer; HBV, hepatitis B virus; HCV, hepatitis C virus; IQR, interquartile range; NASH, nonalcoholic steatohepatitis; UNOS, United Network for Organ Sharing.
^aFor comparison of chemoembolization and radioembolization, obtained using the Fisher exact test or the χ^2 test except for tumor size, for which the Mann-Whitney test was used.

multifocal disease. This suggests that measurement of the primary index lesion alone was able to capture the therapeutic benefit on TTP and survival of an imaging response in that lesion.

Treatment Group and Survival

The difference in patient survival between chemoembolization (median, 17.4 months) and radioembolization (median,

20.5 months) using the Kaplan-Meier method was not significant ($P=.23$). The eFigure presents a survival comparison between treatment groups adjusted for covariates using the Cox proportional hazards model ($P=.12$).

Multivariate Analyses

eTable 2 presents results of the univariate and multivariate analyses. Vari-

ables entered into the multivariate Cox model included age, baseline α -fetoprotein level, Child-Pugh class, UNOS stage, ECOG performance status, and WHO and EASL guidelines response.

Multivariate analysis confirmed the following as significant prognosticators of survival: baseline ECOG performance status 0 (HR, 0.65; 95% CI, 0.43-0.97), UNOS stage less than T4a (HR, 0.62; 95% CI, 0.41-0.95), Child-Pugh class less than C (HR, 0.18; 95% CI, 0.05-0.59), WHO response (HR, 0.55; 95% CI, 0.35-0.84), EASL response (HR, 0.54; 95% CI, 0.34-0.85), and pretreatment α -fetoprotein level of 200 ng/L or less (HR, 0.59; 95% CI, 0.37-0.94). The FIGURE illustrates the survival distribution function by WHO and EASL response, respectively, adjusted for covariates.

Table 2. Intermethod Agreement Between RECIST and WHO Guidelines

WHO	RECIST				No. (%)	κ (95% CI)
	Response		Disease			
	Complete	Partial	Stable	Progressive		
n = 50 (25 + 25)^a						
Response						0.81 (0.66-0.95)
Complete	1	0	0	0	1 (2)	
Partial	0	18	2	1	21 (42)	
Disease						
Stable	0	1	20	0	21 (42)	
Progressive	0	0	2	5	7 (14)	
No. (%)	1 (2)	19 (38)	24 (48)	6 (12)		
n = 100 (50 + 50)						
Response						0.83 (0.73-0.92)
Complete	3	0	0	0	3 (3)	
Partial	0	34	3	1	38 (38)	
Disease						
Stable	0	3	40	1	44 (44)	
Progressive	0	0	3	12	15 (15)	
No. (%)	3 (3)	37 (37)	46 (46)	14 (14)		
n = 150 (75 + 75)						
Response						0.85 (0.78-0.93)
Complete	3	0	0	0	3 (2)	
Partial	0	57	3	1	61 (40.7)	
Disease						
Stable	0	4	59	2	65 (43.3)	
Progressive	0	0	4	17	21 (14)	
No. (%)	3 (2)	61 (41)	66 (44)	20 (13)		
n = 200 (100 + 100)						
Response						0.84 (0.78-0.91)
Complete	4	0	0	0	4 (2)	
Partial	0	76	6	1	83 (41.5)	
Disease						
Stable	0	5	76	2	83 (41.5)	
Progressive	0	0	6	24	30 (15)	
No. (%)	4 (2)	81 (41)	88 (44)	27 (14)		
n = 245 (122 + 123)						
Response						0.86 (0.80-0.92)
Complete	4	0	0	0	4 (1.6)	
Partial	0	92	7	1	100 (40.8)	
Disease						
Stable	0	5	101	2	108 (44.1)	
Progressive	0	0	6	27	33 (13.5)	
No. (%)	4 (2)	97 (40)	114 (47)	30 (12)		

Abbreviations: CI, confidence interval; RECIST, Response Evaluation Criteria in Solid Tumors; WHO, World Health Organization.

^aNumbers in parentheses indicate numbers by treatment group (chemoembolization + radioembolization). κ Calculated at increments of 25 random patients per treatment group (except final increment, as shown), with final κ coefficients based on all 245 patients.

COMMENT

Novel LRTs are establishing their role in the management of HCC, necessitating the ability to accurately determine tumor response.^{4,5,28} For LRTs, standardization in methodology and evidence are lacking.¹³ In this analysis, we sought to test agreement between RECIST (unidimensional), WHO (bidimensional), and EASL (necrosis) guidelines, as well as to validate the clinical benefit imparted by observing response by correlating imaging response to TTP and survival. Lastly, the concept of the primary index lesion was introduced, potentially leading to a novel methodology for standardization of response and analyses of time to end point in patients with HCC who are receiving transarterial LRTs.

Although pretreatment and post-treatment determinations of tumor volume (3-dimensional) are intuitively most representative of actual treatment effect, limitations in available technology prevent their routine use.²⁹ Our data validate that the WHO (bidimensional) and RECIST (unidimensional) guidelines are similar in assessing change in size when applied to transarterial LRTs.¹⁵ The intermethod agreement was high ($\kappa=0.86$). Thus,

given that tumors usually are not spherical and have irregular borders, we prefer using WHO over RECIST guidelines for transarterial LRTs, particularly when the patient sample size is small. On the other hand, there was minimal intermethod agreement between necrosis and size guidelines (EASL vs WHO, $\kappa=0.28$; EASL vs RECIST, $\kappa=0.24$). These findings are intuitive; a complete response by EASL could be classified as a complete response, partial response, stable disease, or progressive disease by WHO or RECIST guidelines. Keppke et al¹¹ confirmed this, reporting response rates of 23%, 26%, and 57% with application of RECIST, WHO, and EASL guidelines, respectively. These findings were further confirmed by Forner et al¹⁰ ($\kappa=0.19$ between EASL and RECIST guidelines).

The development of systemic biologic therapies in the management of HCCs, particularly those that are cytostatic rather than cytotoxic, necessitates the ability to measure response despite no change in tumor size.³ The imaging characteristics and response rates following LRTs can be heterogeneous at the lesional level; this is potentially related to anomalous blood supply to HCCs.³⁰ Ablative techniques have been shown to cause necrosis without affecting tumor size.¹⁰ Complete response by EASL at 1 month following percutaneous therapies correlates with improved survival.¹⁶ The presence of residual tumor at 1 month following ablation may indicate incomplete targeting of tumor. Thus, unlike complete response, a partial response by EASL guidelines (potentially representing treatment failure) may not necessarily indicate improved outcomes following thermal ablation.¹⁶ As seen in this study, transarterial LRTs have been shown to affect both size and necrosis as seen in this study, with both translating into favorable long-term outcomes.³¹

Since EASL partial response is usually manifest at 1.6 months, one could postulate that EASL response may serve as an earlier surrogate for

therapeutic benefit when compared with WHO response. Response by EASL also may have an important role in patients with HCC who are listed for liver transplantation, because time from treatment to

Table 3. Intermethod Agreement Between Size (WHO and RECIST) and Necrosis (EASL) Guidelines (N = 245)

Guideline	EASL				No. (%)	κ (95% CI)
	Response		Disease			
	Complete	Partial	Stable	Progressive		
RECIST						
Response						0.24 (0.16-0.33)
Complete	4	0	0	0	4 (1.6)	
Partial	37	49	8	3	97 (39.6)	
Disease						
Stable	32	34	44	4	114 (46.5)	
Progressive	6	10	2	12	30 (12.3)	
No. (%)	79 (32)	93 (38)	54 (22)	19 (8)		
WHO						
Response						0.28 (0.19-0.36)
Complete	4	0	0	0	4 (1.6)	
Partial	36	54	7	3	100 (40.8)	
Disease						
Stable	33	30	43	2	108 (44.1)	
Progressive	6	9	4	14	33 (13.5)	
No. (%)	79 (32)	93 (38)	54 (22)	19 (8)		

Abbreviations: CI, confidence interval; EASL, European Association for Study of the Liver; RECIST, Response Evaluation Criteria in Solid Tumors; WHO, World Health Organization.

Table 4. Comparison of Survival Between Responders and Nonresponders Substratified by Tumor Distribution (Solitary vs Multifocal Disease)


Guideline ^a	No. (%)	TTP		Survival	
		HR (95% CI)	P Value ^b	HR (95% CI)	P Value ^b
WHO					
Total			<.001		<.001
Responders	104 (42)	0.36 (0.23-0.57)		0.46 (0.32-0.67)	
Nonresponders	141 (58)	1 [Reference]		1 [Reference]	
Solitary disease					
Responders	48 (43)	0.25 (0.12-0.54)	.001	0.39 (0.19-0.77)	.01
Nonresponders	64 (57)	1 [Reference]		1 [Reference]	
Multifocal disease					
Responders	56 (42)	0.49 (0.29-0.85)	.02	0.51 (0.32-0.82)	.01
Nonresponders	77 (58)	1 [Reference]		1 [Reference]	
EASL					
Total			<.001		<.001
Responders	172 (70)	0.38 (0.22-0.64)		0.36 (0.22-0.57)	
Nonresponders	73 (30)	1 [Reference]		1 [Reference]	
Solitary disease					
Responders	85 (76)	0.26 (0.09-0.66)	.009	0.26 (0.1-0.67)	.01
Nonresponders	27 (24)	1 [Reference]		1 [Reference]	
Multifocal disease					
Responders	87 (65)	0.49 (0.27-0.92)	.05	0.47 (0.28-0.79)	.009
Nonresponders	46 (35)	1 [Reference]		1 [Reference]	

Abbreviations: CI, confidence interval; EASL, European Association for Study of the Liver; HR, hazard ratio; TTP, time to progression; WHO, World Health Organization.

^a“Responder” refers to the patients achieving either complete or partial response.

^bAdjusted for multiple comparisons.

Figure. Survival by WHO and EASL Response Criteria, Adjusted by Covariates



Response refers to patients achieving either partial or complete response. Analyses were adjusted for age, baseline α -fetoprotein level, Child-Pugh class, United Network for Organ Sharing stage, and Eastern Cooperative Oncology Group performance status. EASL indicates European Association for Study of the Liver; WHO, World Health Organization.

transplantation is variable and because EASL response is achieved earlier. The median time to WHO response was 7.7 months. A lesion that has decreased in size (WHO response) has stood the test of time, suggesting favorable tumor biology and the ability of the surrounding hepatic parenchyma to regenerate normally. The HRs for survival of responders vs nonresponders by WHO and EASL were similar on multivariate analysis (0.55 and 0.54, respectively). These data suggest that EASL response (achieved early) and WHO response (achieved later and therefore time-tested) are both important parameters and are independent predictors of survival.

In patients with solitary HCC, the primary index lesion is clearly represented by the single tumor nodule that undergoes treatment. However, with multifocal disease, the ability to capture response and time-to-event end points becomes less evident given the multiplicity of tumors and staged treatment points.

Given these realities, can the concept of the primary index lesion be expanded to multifocal disease? There are 3 rationales for hypothesizing the potential clinical utility of the index lesion in multifocal disease. First, LRTs are performed as staged

procedures and hence, as opposed to systemic therapies, not all lesions are treated at the same time, resulting in variable starting points for response and time-to-progression analyses. Second, not all patients being treated with LRTs undergo a complete treatment cycle (patients may have progressive disease, experience adverse events, or be intolerant to further treatment). This would result in a confounding mathematical effect of overall response being dependent on the magnitude of the size changes of treated and untreated tumors, potentially erroneously leading to the reporting of stable or even progressive disease rather than response to therapy. Third, response assessment, TTP, and survival are inherently flawed if they are measured from the end of the treatment cycle, because it may take 2 to 6 months to treat all disease. This would make comparison of LRTs with systemic agents (eg, TTP using sorafenib, 5.5 months) and hypothesis generation for future clinical trials, in which analyses of time to end point begin at the time of protocol enrollment or randomization, difficult.³

Our analysis suggests that response seen in the primary index lesion following treatment, even in the presence of multifocal disease, showed a prog-

nostic benefit following LRTs. In some sense, the primary index lesion was able to serve as a biomarker of long-term outcomes. The HRs using WHO and EASL were able to capture the significant TTP and survival benefit in responders vs nonresponders in patients with solitary and multifocal HCC. Furthermore, responses by WHO (bidimensional) and EASL (necrosis) guidelines had independent effects on survival in multivariate analysis.

This study has limitations. The study includes patients treated with chemoembolization or with radioembolization using ⁹⁰Y. However, the baseline characteristics of the 2 treatment groups by Child-Pugh class, BCLC class, and UNOS stage were identical. Survival between the 2 treatment groups was not significantly different. In contradistinction to the data used to formulate the original RECIST guidelines (different malignancies, various systemic therapies), our analysis is more standardized, because it is based only on HCC. Few studies have compared size and enhancement guidelines for assessing tumor response.¹⁰ Although pathological evaluation of the treated lesion represents the gold standard for assessing response to treatment, this is available only in select cases following resection, transplantation, or autopsy.^{31,32} The therapeutic benefit of imaging and other biomarkers must be studied.³³ It would be interesting to investigate if the same concept of primary index lesion holds for ablative LRTs or systemic therapy.

In conclusion, WHO and RECIST guidelines had minimal agreement with EASL guidelines.¹⁰ The WHO and EASL guidelines responses were favorable and independent prognostic factors of survival. No imaging guidelines are currently considered the gold standard for LRTs. The combined findings of response at the primary index lesion level being predictive of TTP and survival, the significant HR for TTP and survival in solitary and multifocal disease, and the significant HRs for survival maintained in the

multivariate analyses all support the use of the primary index lesion as a biomarker to assess imaging response following transarterial LRTs. This may potentially lead to simplification, reproducibility, and standardization of imaging assessment guidelines in LRTs. Measuring the primary index lesion and then starting analyses of time to end point at the time of first treatment (irrespective of completion of the treatment plan) is in keeping with the principles of intention-to-treat. It should be stressed that patients should continue to receive

the planned treatment to target all disease, even in the presence of response in the primary index lesion. The findings presented herein will require further validation.

Author Contributions: Dr Salem had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Riaz, Kulik, Lewandowski, Mulcahy, Wang, Benson, Nemcek, Omary, Salem.

Acquisition of data: Riaz, Kulik, Lewandowski, Ryu, Sato, Omary, Salem.

Analysis and interpretation of data: Riaz, Miller, Kulik, Nikolaidis, Yaghmai, Lewandowski, Mulcahy, Ryu, Sato, Gupta, Wang, Baker, Abecassis, Benson, Nemcek, Omary, Salem.

Drafting of the manuscript: Riaz, Salem.

Critical revision of the manuscript for important in-

tellectual content: Riaz, Miller, Kulik, Nikolaidis, Yaghmai, Lewandowski, Mulcahy, Ryu, Sato, Gupta, Wang, Baker, Abecassis, Benson, Nemcek, Omary, Salem.

Statistical analysis: Riaz, Wang, Salem.

Administrative, technical, or material support: Riaz, Salem.

Study supervision: Riaz, Miller, Kulik, Nikolaidis, Yaghmai, Lewandowski, Mulcahy, Ryu, Sato, Gupta, Wang, Baker, Abecassis, Benson, Nemcek, Omary, Salem.

Financial Disclosures: Dr Benson reported serving as an advisor to, and receiving grant support from, MDS Nordion. Dr Omary and Dr Salem reported being supported in part by National Institutes of Health grant R01 CA126809. Dr Salem reported serving as consultant to, and receiving grant support from, MDS Nordion. None of the other authors reported any disclosures.

Online-Only Material: eTables 1 and 2 and the eFigure are available at <http://www.jama.com>.

REFERENCES

1. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. *Hepatology*. 2002;36(5)(suppl 1):S74-S83.
2. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. *N Engl J Med*. 1996;334(11):693-699.
3. Llovet JM, Ricci S, Mazzaferro V, et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med*. 2008;359(4):378-390.
4. Kulik LM, Atassi B, van Holsbeeck L, et al. Yttrium-90 microspheres (TheraSphere(R)) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. *J Surg Oncol*. 2006;94(7):572-586.
5. Maddala YK, Stadheim L, Andrews JC, et al. Drop-out rates of patients with hepatocellular carcinoma listed for liver transplantation: outcome with chemoembolization. *Liver Transpl*. 2004;10(3):449-455.
6. Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. *Gastroenterology*. 2010;138(1):52-64.
7. Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. *Am J Transplant*. 2009;9(8):1920-1928.
8. World Health Organization (WHO). *WHO Handbook for Reporting Results of Cancer Treatment*. Geneva, Switzerland: WHO; 1979. WHO offset publication No.48.
9. Therasse P, Arbuuck SG, Eisenhauer EA, et al; European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. New guidelines to evaluate the response to treatment in solid tumors. *J Natl Cancer Inst*. 2000;92(3):205-216.
10. Forner A, Ayuso C, Varela M, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? *Cancer*. 2009;115(3):616-623.
11. Keppke AL, Salem R, Reddy D, et al. Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres. *AJR Am J Roentgenol*. 2007;188(3):768-775.
12. Bruix J, Sherman M, Llovet JM, et al; EASL Panel of Experts on HCC; European Association for the Study of the Liver. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference. *J Hepatol*. 2001;35(3):421-430.
13. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer*. 2009;45(2):228-247.
14. Hillman SL, An MW, O'Connell MJ, et al. Evaluation of the optimal number of lesions needed for tumor evaluation using the response evaluation criteria in solid tumors: a North Central Cancer Treatment Group investigation. *J Clin Oncol*. 2009;27(19):3205-3210.
15. Park JO, Lee SI, Song SY, et al. Measuring response in solid tumors: comparison of RECIST and WHO response criteria. *Jpn J Clin Oncol*. 2003;33(10):533-537.
16. Sala M, Llovet JM, Vilana R, et al; Barcelona Clinic Liver Cancer Group. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. *Hepatology*. 2004;40(6):1352-1360.
17. Bruix J, Llovet JM, Castells A, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. *Hepatology*. 1998;27(6):1578-1583.
18. Llovet JM, Fuster J, Bruix J; Barcelona-Clinic Liver Cancer Group. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. *Liver Transpl*. 2004;10(2)(suppl 1):S115-S120.
19. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. *Gastroenterology*. 2008;134(6):1752-1763.
20. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. *Gastroenterology*. 2004;127(5)(suppl 1):S179-S188.
21. Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 1: technical and methodologic considerations. *J Vasc Interv Radiol*. 2006;17(8):1251-1278.
22. Landis JR, Koch GG. The measurement of observer agreement for categorical data. *Biometrics*. 1977;33(1):159-174.
23. Svanholm H, Starklint H, Gundersen HJ, Fabricius J, Barlebo H, Olsen S. Reproducibility of histomorphologic diagnoses with special reference to the kappa statistic. *APMIS*. 1989;97(8):689-698.
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. *J Am Stat Assoc*. 1958;53:457-481.
25. Llovet JM, Di Bisceglie AM, Bruix J, et al; Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma. *J Natl Cancer Inst*. 2008;100(10):698-711.
26. Bradburn MJ, Clark TG, Love SB, Altman DG. Survival analysis, III: multivariate data analysis—choosing a model and assessing its adequacy and fit. *Br J Cancer*. 2003;89(4):605-611.
27. Schoenfeld DA. Sample-size formula for the proportional-hazards regression model. *Biometrics*. 1983;39(2):499-503.
28. Lu DS, Yu NC, Raman SS, et al. Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. *Radiology*. 2005;234(3):954-960.
29. Toso C, Trotter J, Wei A, et al. Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. *Liver Transpl*. 2008;14(8):1107-1115.
30. Chung JW, Kim HC, Yoon JH, et al. Transcatheter arterial chemoembolization of hepatocellular carcinoma: prevalence and causative factors of extrahepatic collateral arteries in 479 patients. *Korean J Radiol*. 2006;7(4):257-266.
31. Riaz A, Kulik L, Lewandowski RJ, et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. *Hepatology*. 2009;49(4):1185-1193.
32. Riaz A, Lewandowski RJ, Kulik L, et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization [published online ahead of print December 5, 2009]. *Cardiovasc Intervent Radiol*. 2009. doi:10.1007/s00270-009-9766-5.
33. Riaz A, Ryu RK, Kulik LM, et al. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. *J Clin Oncol*. 2009;27(34):5734-5742.